Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)

A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3.

The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme binary outcomes, the market saw one of the most significant single-day collapses in recent history alongside a

Here are the top movers in Monday's session, showcasing the stocks with significant price changes.

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.

Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday.

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Ultragenyx Q2 2025 earnings show revenue beat and narrower loss, reaffirming full-year guidance. Shares rose slightly post-report amid mixed market sentiment.

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by year-end.

Ultragenyx's UX111 gene therapy faces FDA delay due to facility issues; analysts adjust price targets amid uncertain resubmission timeline.

The company has a bigger problem than just the FDA rejection, says one analyst. It's timeline to profitability is now longer.

Investors shrug off tariff drama as earnings, chip euphoria, and airline optimism steal the show.